Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports.
The aim of this study was to assess whether use of selective serotonin reuptake inhibitors (SSRIs) is associated with extrapyramidal syndromes (EPS). We analysed the spontaneous reports of adverse drug reactions (ADRs) collected by The Netherlands Pharmacovigilance Foundation Lareb in the period 1985-99 (n = 24,263). The study population comprised all patients using an antidepressant drug at the time the ADR occurred. We calculated ADR-reporting odds ratios (ADR-OR) to estimate the association between SSRI-use and EPS, relative to other antidepressants. We identified 61 patients with EPS. SSRI-use was associated with spontaneous reporting of EPS compared to other antidepressants (adjusted ADR-OR 2.2; 95% confidence interval 1.2-3.9). This risk estimate appeared to be higher in patients concurrently using antipsychotic medication (6.9, 0.7-68.0), although the confidence interval was very wide. In conclusion, SSRI-use seems only to be moderately associated with EPS compared to other antidepressants. However, those concurrently using antipsychotic drugs or presenting with other risk factors may be more susceptible and should be closely monitored.
Schillevoort
I
I
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands. i.e.r.m.schillevoort@pharm.uu.nl
van Puijenbroek
E P
EP
de Boer
A
A
Roos
R A C
RA
Jansen
Paul A F
PA
Leufkens
H G M
HG
D000368:Aged; D000928:Antidepressive Agents / Q000009:adverse effects; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000453:epidemiology; D016022:Case-Control Studies; D016208:Databases, Factual; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D011358:Product Surveillance, Postmarketing; D012148:Restless Legs Syndrome / Q000139:chemically induced / Q000453:epidemiology; D018570:Risk Assessment; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*
D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors